1. Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study 
N. Lerolle, E. Raffoux, G. Socie, S. Touratier, H. Sauvageon, R. Porcher, S. Bretagne, A. Bergeron, E. Azoulay, J.-M. Molina, M. Lafaurie 
Clinical Microbiology and Infection 
Volume 20, Issue 11, Pages O952-O959 (November 2014)
DOI: /
Copyright © 2014 European Society of Clinical Infectious Diseases Terms and Conditions

2. FIG. 1
Study flow-chart of patients included in the study. PSC, posaconazole; AML, acute myeloid leukaemia; GVHD, graft-versus-host disease; AHSCT, allogenic haematopoietic stem cell transplantation; IAA, idiopathic aplastic anaemia; MDS, myelodysplastic syndrome; IFD, invasive fungal infection.
Clinical Microbiology and Infection  , O952-O959DOI: ( / )
Copyright © 2014 European Society of Clinical Infectious Diseases Terms and Conditions